Follicular lymphoma (FL) is the second most common form of NHL ... inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has returned after two or more prior treatments a new ...

Some antigenic stimuli may result in lymphoid proliferations that exhibit worrisome cytoarchitectural features but do not fulfill the full criteria for the diagnosis of lymphoma – that is ...